Kalkine has a fully transformed New Avatar.

Last update at 2026-03-10T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Exploring May 2025's Undervalued Small Caps With Insider Activity
Fri 23 May 25, 11:39 AMReflecting On Healthcare Technology for Providers Stocks’ Q1 Earnings: Evolent Health (NYSE:EVH)
Thu 22 May 25, 03:34 AMOmnicell's New Perioperative Clinic Setting Products May Boost Stock
Thu 15 May 25, 12:55 PMOmnicell Announces New Products for Perioperative and Clinic Settings
Wed 14 May 25, 08:01 PMOmnicell Opens New Innovation Lab in Austin, Texas
Wed 14 May 25, 12:30 PMHealthcare Technology for Providers Stocks Q1 Earnings Review: Premier (NASDAQ:PINC) Shines
Wed 14 May 25, 03:32 AM2 Healthcare Stocks with Promising Prospects and 1 to Think Twice About
Mon 12 May 25, 04:42 AMOmnicell, Inc. (NASDAQ:OMCL) Just Reported, And Analysts Assigned A US$38.50 Price Target
Fri 09 May 25, 11:19 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -2.45300M | 66.01M | 29.35M | 73.93M | 35.62M |
| Minority interest | - | - | - | - | - |
| Net income | 5.65M | 77.85M | 32.19M | 61.34M | 37.73M |
| Selling general administrative | 486.34M | 389.43M | 307.61M | 289.92M | 263.10M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 588.99M | 554.65M | 413.29M | 436.91M | 372.33M |
| Reconciled depreciation | 99.17M | 84.93M | 71.59M | 64.12M | 51.35M |
| Ebit | -2.32300M | 89.51M | 35.53M | 78.35M | 44.39M |
| Ebitda | 96.85M | 174.44M | 107.12M | 142.47M | 95.74M |
| Depreciation and amortization | 99.17M | 84.93M | 71.59M | 64.12M | 51.35M |
| Non operating income net other | -0.13000M | -23.50000M | -6.17700M | -4.41900M | -8.77600M |
| Operating income | -2.32300M | 89.51M | 35.53M | 78.35M | 44.39M |
| Other operating expenses | 1298.27M | 1042.51M | 856.68M | 818.67M | 742.92M |
| Interest expense | 0.13M | -23.50000M | -6.17700M | -4.41900M | 8.78M |
| Tax provision | -8.10100M | -11.84200M | -2.84500M | 12.60M | -2.11300M |
| Interest income | - | - | - | 4.42M | 8.78M |
| Net interest income | -0.13000M | -23.50000M | -6.17700M | -4.41900M | -8.77600M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -8.10100M | -11.84200M | -2.84500M | 12.60M | -2.11300M |
| Total revenue | 1295.95M | 1132.02M | 892.21M | 897.03M | 787.31M |
| Total operating expenses | 591.31M | 465.15M | 377.77M | 358.56M | 327.94M |
| Cost of revenue | 706.96M | 577.37M | 478.92M | 460.12M | 414.98M |
| Total other income expense net | -0.13000M | -23.50000M | -6.17700M | -4.41900M | -8.77600M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 5.65M | 77.85M | 32.19M | 61.34M | 37.73M |
| Net income applicable to common shares | 5.65M | 77.85M | 32.19M | 61.34M | 37.73M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 2226.88M | 2210.76M | 2142.50M | 1824.50M | 1240.81M |
| Intangible assets | 277.83M | 242.91M | 277.62M | 168.21M | 124.87M |
| Earning assets | - | - | - | - | - |
| Other current assets | 52.60M | 77.36M | 48.33M | 41.04M | 15.18M |
| Total liab | 1037.92M | 1080.62M | 995.81M | 857.00M | 395.56M |
| Total stockholder equity | 1188.95M | 1130.14M | 1146.69M | 967.50M | 845.25M |
| Deferred long term liab | - | 2.10M | 51.70M | 4.25M | 39.09M |
| Other current liab | 179.96M | 235.35M | 204.30M | 123.86M | 89.66M |
| Common stock | 0.06M | 0.06M | 0.05M | 0.05M | 0.05M |
| Capital stock | 0.06M | 0.06M | 0.05M | 0.05M | 0.05M |
| Retained earnings | 370.36M | 390.73M | 368.57M | 290.72M | 258.79M |
| Other liab | - | 46.20M | 79.74M | 64.48M | 57.89M |
| Good will | 735.81M | 734.27M | 738.90M | 499.31M | 336.54M |
| Other assets | - | 138.99M | 225.59M | 268.50M | 100.72M |
| Cash | 500.98M | 330.36M | 349.05M | 485.93M | 127.21M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 367.79M | 428.45M | 876.16M | 276.42M | 237.00M |
| Current deferred revenue | 132.28M | 118.95M | 112.20M | 100.05M | 90.89M |
| Net debt | 113.11M | 286.38M | 179.01M | 30.17M | -26.54100M |
| Short term debt | 10.52M | 10.76M | 488.15M | 12.20M | 10.06M |
| Short long term debt | - | - | 488.15M | - | - |
| Short long term debt total | 614.09M | 616.74M | 528.06M | 516.10M | 100.67M |
| Other stockholder equity | 831.97M | 756.44M | 786.47M | 682.25M | 595.86M |
| Property plant equipment | - | 93.96M | 119.69M | 59.07M | 54.25M |
| Total current assets | 927.57M | 881.81M | 780.70M | 829.41M | 483.24M |
| Long term investments | 42.95M | 32.92M | 18.39M | 22.16M | 19.75M |
| Net tangible assets | - | 152.96M | 130.17M | 967.50M | 845.25M |
| Short term investments | 11.87M | 11.49M | 10.66M | 10.25M | - |
| Net receivables | 263.89M | 299.47M | 240.89M | 190.12M | 218.36M |
| Long term debt | 569.66M | 566.57M | - | 467.20M | 50.00M |
| Inventory | 110.10M | 147.55M | 119.92M | 96.30M | 108.01M |
| Accounts payable | 45.03M | 63.39M | 71.51M | 40.31M | 46.38M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -13.43200M | -17.08700M | -8.40700M | -5.52200M | -9.44600M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.06M | 0.05M | 0.05M | 0.05M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 390.73M | 368.57M | 290.72M | 258.79M |
| Treasury stock | - | -290.31900M | -238.10900M | -238.10900M | -185.07400M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 64.37M | 164.50M | 191.31M | 176.21M | 151.90M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1299.31M | 1328.95M | 1361.79M | 995.09M | 757.57M |
| Capital lease obligations | 44.43M | 50.17M | 39.91M | 48.90M | 60.73M |
| Long term debt total | - | 566.57M | - | 467.20M | 50.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -58.66900M | -412.49800M | -279.86600M | -61.66400M | -54.37400M |
| Change to liabilities | 10.64M | 53.26M | 17.12M | 19.44M | 11.82M |
| Total cashflows from investing activities | -58.66900M | -412.49800M | -279.86600M | -61.66400M | -54.37400M |
| Net borrowings | - | - | 408.49M | -92.32100M | -77.00000M |
| Total cash from financing activities | -20.95300M | 47.36M | 456.27M | -23.47900M | -13.59700M |
| Change to operating activities | 0.29M | 10.06M | -13.22100M | 0.52M | 8.37M |
| Net income | 5.65M | 77.85M | 32.19M | 61.34M | 37.73M |
| Change in cash | -2.78500M | -134.30000M | 362.71M | 60.02M | 34.77M |
| Begin period cash flow | 355.62M | 489.92M | 127.21M | 67.19M | 32.42M |
| End period cash flow | 352.83M | 355.62M | 489.92M | 127.21M | 67.19M |
| Total cash from operating activities | 77.78M | 231.81M | 185.87M | 145.01M | 103.97M |
| Issuance of capital stock | - | 0.00000M | 0.00000M | 37.81M | 39.57M |
| Depreciation | 99.17M | 84.93M | 71.59M | 64.12M | 51.35M |
| Other cashflows from investing activities | -11.13300M | -383.53100M | -257.02400M | -45.77000M | -30.67700M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -30.11500M | -25.69500M | 12.36M | -8.12300M | -6.76300M |
| Change to account receivables | -60.35700M | -43.22000M | 12.03M | -23.52000M | -6.19200M |
| Sale purchase of stock | -52.21000M | 67.35M | -53.03500M | 78.51M | 70.18M |
| Other cashflows from financing activities | 31.26M | 47.36M | 709.30M | 28.71M | 23.84M |
| Change to netincome | 31.61M | 50.32M | 38.42M | 33.16M | 23.31M |
| Capital expenditures | 60.74M | 58.34M | 54.87M | 61.66M | 54.37M |
| Change receivables | -75.71100M | -37.62700M | 33.96M | -25.23900M | -7.87200M |
| Cash flows other operating | 44.61M | 10.61M | -15.61600M | 8.68M | -7.90600M |
| Exchange rate changes | - | -0.97400M | 0.44M | 0.15M | -1.22700M |
| Cash and cash equivalents changes | -1.84100M | -134.30000M | 362.71M | 60.02M | 34.77M |
| Change in working capital | -73.46600M | -3.34000M | 37.30M | -15.81000M | -10.71800M |
| Stock based compensation | 68.25M | 53.16M | 44.70M | 34.05M | 28.89M |
| Other non cash items | 15.50M | 22.48M | 6.63M | 2.65M | 2.42M |
| Free cash flow | 17.04M | 173.47M | 131.00M | 83.34M | 49.59M |
Sector: Healthcare Industry: Health Information Services
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| OMCL Omnicell Inc |
-0.84 2.11% | 38.99 | - | 29.50 | 1.09 | 1.05 | 1.21 | 22.79 |
| GEHC GE HealthCare Technologies Inc. |
-2.9 3.83% | 72.73 | 22.91 | 20.12 | 2.01 | 5.52 | 2.39 | 13.30 |
| VEEV Veeva Systems Inc Class A |
-5.88 3.01% | 189.69 | 54.61 | 33.22 | 12.83 | 6.73 | 11.14 | 58.84 |
| MTHRF M3 Inc |
- -% | 11.42 | 29.72 | 25.00 | 0.05 | 4.38 | 0.04 | 0.12 |
| MTHRY M3 Inc |
-0.07 1.34% | 5.17 | 31.84 | 26.25 | 0.05 | 4.60 | 0.04 | 0.12 |
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
4220 North Freeway, Fort Worth, TX, United States, 76137
| Name | Title | Year Born |
|---|---|---|
| Mr. Randall A. Lipps | Founder, Exec. Chairman, Pres & CEO | 1957 |
| Mr. Peter J. Kuipers | Exec. VP & CFO | 1972 |
| Ms. Christine Mellon | Exec. VP, Chief Admin. & People Officer | 1963 |
| Mr. Scott Peter Seidelmann | Exec. VP & Chief Commercial Officer | 1976 |
| Mr. Joseph Brian Spears | Sr. VP, Chief Accounting Officer & Corp. Controller | 1960 |
| Mr. Giri Chodavarapu | Sr. VP & Chief Information Officer | NA |
| Ms. Kathleen Nemeth | Sr. VP of Investor Relations | NA |
| Mr. Corey J. Manley | Sr. VP & Chief Legal Officer | NA |
| Ms. Roxanne Turner | Sr. VP of Corp. Responsibility and Chief Compliance & Privacy Officer | NA |
| Mr. Jorge R. Taborga | Exec. VP of Engineering & Integration Management Officer | 1959 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.